ADVENTRX and SynthRx, a private biotechnology company, completed a definitive merger on April 8, 2011.
New software being used at Englewood Hospital and Medical Center should help detect prostate cancer earlier, eliminate unnecessary testing procedures and help form a treatment plan.
A new market research report on the In Vitro Diagnostic market is now available in the reportlinker.com catalogue.
EpiCept Corporation Announces Year End Results and Updates On Clinical Trials Surrounding Cancer Treatment
EpiCept Corporation recently announced operating and financial results for the year 2010, and provided an update on its key business initiatives.
The core theory behind preventative medicine is almost psychic. To stop a disease from wielding its mighty weapons before it occurs is based on foreknowledge of a patient’s susceptibility to the illness.